2022
DOI: 10.1177/13524585211067708
|View full text |Cite
|
Sign up to set email alerts
|

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—Commentary

Abstract: 10. Baker D, Pryce G, James LK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020; 44: 102279. Visit SAGE journals online journals.sagepub.com/ home/msj

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 10 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?